What should I do if I develop drug resistance using trastuzumab injection (subcutaneous injection) (Herceptin Hylecta)?

The U.S. Food and Drug Administration (FDA)approvedHER2-targeted therapies include monoclonal antibodies (such as trastuzumab andpertuzumab, antibody-drug conjugates (such as T-DM1 and DS-8201) and small molecule HER1/2 TKIs (such as lapatinib, neratinib, and tucatinib) are also a form of trastuzumab.

If resistance occurs when using trastuzumab injection (subcutaneous injection), patients are advised to contact their doctor or medical team immediately. The doctor may consider increasing the dose of trastuzumab to improve its efficacy, but this needs to be evaluated based on the patient's specific situation and under the supervision of a doctor. Doctors may also recommend taking trastuzumab in combination with other drugs to enhance the effectiveness of the treatment. For example, in combination with other chemotherapy drugs, targeted therapy drugs, or radiation therapy. If resistance to trastuzumab injection (subcutaneous injection) is severe, your doctor may recommend trying other alternative treatments. There are many other targeted therapies available. Everyone’s constitution is different and their resistance to drugs is also different. If drug resistance develops after using the drug, please inform your doctor in time and do not adjust the drug dosage yourself.

It is understood that the original drug of trastuzumab injection (subcutaneous injection) has been launched in China, but the specific price and other relevant information are not yet clear. Since the drug has been on the market for a short time, it has not been included in the scope of medical insurance. At present, there are no generic drugs of Trastuzumab injection (subcutaneous injection) produced and marketed. For more information and specific prices of Trastuzumab injection (subcutaneous injection), please consult a medical consultant.